MK-2206
- Generic Name
- MK-2206
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H21N5O
- CAS Number
- 1032349-93-1
- Unique Ingredient Identifier
- 51HZG6MP1K
- Associated Conditions
- -
- Associated Therapies
- -
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Phase 2
Terminated
- Conditions
- Metastatic Kidney CarcinomaRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7Stage III Renal Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT01239342
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAcute Undifferentiated LeukemiaAggressive NK-cell LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous LeukemiaChronic Phase Chronic Myelogenous LeukemiaMast Cell Leukemia
- Interventions
- Drug: Akt inhibitor MK2206Other: diagnostic laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT01231919
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath